Summary

At a 2025 Pitch Night, John Birch shared a candid, behind‑the‑scenes account of building Quantec—from its beginnings as a science‑led dairy IP venture to a commercial supplements and skincare company. He spoke about surviving multiple near‑death moments through constant pivoting, applying strong IP discipline with a commercial mindset, staying frugal, choosing values‑aligned partners, and fostering a people‑first culture.

The company learned hard truths about channel concentration in China, the risks of exclusive distribution, and the difficulty of licensing to big brands without in‑market proof. Post‑COVID, they recapitalised by divesting non‑core/parked IP, rebuilt China with non‑exclusive partners, returned capital and paid a dividend, and “Quantec Horizons” to pursue future IP only when there’s a clear line‑of‑sight to commercialisation.

Short timeline

• 2006: Discovery of IDP; early vision for a natural mastitis remedy and human health potential.
• 2011: First “smart money” in—only after a convincing monetisation plan emerged.
• 2013–2017 (approx.): Strong acne study; Epiology launches; brand‑building proves costly; an attempted strategic sale collapses after an acquirer change.
• 2019–2020: New China growth deal signed; COVID hits; brick‑and‑mortar freezes; termination and reset.
• 2022–2023: US dairy JV nearly closes; paused due to their internal constraints; recap achieved via non‑core IP sale; capital returned.
• 2024–2025: Non‑exclusive China rebuild, trade‑show presence multiples, dividend paid, Quantec Horizons established to drive future IP with commercial discipline.

Big ideas & takeaways

1. Deep tech roots → IDP discovery
   From NZ dairy engineering, the team identified IDP (immune defence proteins), a milk‑derived suite with stronger combined antimicrobial effects than any single protein. Initial vision: a natural mastitis remedy, with parallel potential in human health.
2. From vet “holy grail” to human skincare
   Even with strong acne clinical outcomes, large skincare players wouldn’t license without in‑market traction. The team launched Epiology as a proof‑of‑concept brand—quickly discovering that brand building is capital‑intensive and culturally different for a science/engineering company.
3. The “three‑legged table” became a “three‑headed monster”
   Running China supplements, Epiology, and pharma/vet mastitis in parallel over‑stretched capital and focus. Each “head” needed cash and attention and believed it was the main act.
4. China distribution: cashflow and control risks
   A single, exclusive distributor (brick‑and‑mortar focused, not category‑native) generated cash but created ongoing control and compliance issues (e.g., exaggerated claims, unintended government association).
   Lesson: Be obsessive about IP/trademark control and beware exclusivity unless it’s performance‑based and enforceable.
5. China capital is slow and relationship‑heavy
   Fundraising proved exceedingly slow with many cycles of meetings and entertainments—an inefficient path for a small NZ firm despite some brand benefit.
6. COVID exposed channel concentration
   Brick‑and‑mortar froze, online capability was missing, and revenue collapsed. The distributor was terminated; the rebuild began remotely amid travel bans.
7. Remote hiring pitfalls in China
   Small in‑market teams can drift culturally, become customer‑aligned vs company‑aligned, and be costly to exit under local employment law. Budget for the real costs of operating in‑market.
8. Survival financing & culture
   With bank debt and no revenue, solvency became a daily concern. Staff converted salaries to convertible notes, and a few shareholders kept injecting cash—driven by values and belief more than short‑term logic.
   Lesson: Survival is the first KPI.
9. Partner fit matters more than the cheque
   A potential buyer with poor business understanding was a bad fit. A major US dairy was values‑aligned and nearly a Joint Venture but hit internal roadblocks; integrity on both sides helped bridge to a later, accretive structure.
10. Recap via IP portfolio surgery
    The team sold non‑core/parked IP to recapitalise, returned capital to shareholders, and reinvested in China with non‑exclusive partners to avoid single‑channel dependency.
11. From recovery to dividends & disciplined growth
    Progressed to paying a dividend without compromising growth. Heavy reinvestment in tech and creation of Quantec Horizons—a ring‑fenced vehicle to pursue future IP only with clear commercialisation.
12. Operating philosophy (why they survived)
• IP + commercial overlay: continue filing and validating with clinical studies tied to marketable claims.
• Culture: curiosity, optimism, frugality (everyone flies economy), and a board that rolls up sleeves.
• Know when to stop: shelve/exit when odds turn.
• Values: play hard but straight; handshakes matter; long‑run trust compounds.

Practical lessons for founders

• Don’t scale three bets at once unless you truly have the capital and leadership bandwidth; otherwise, each bet starves the others.
• Exclusivity is a debt. If you grant it, make it performance‑gated, audit claims rigorously, and design off‑ramps.
• Diversify channels. Build online capability even when retail is humming.
• Proof before partners.  Large corporates usually require in‑market proof and repeatable unit economics before licensing.
• IP with a commercial line‑of‑sight only—avoid “patents in the drawer.”
• Budget real market costs (senior comp, severance, and governance) for China or any complex market.
• Institutionalise survival tools (cash war rooms, convertible‑note payroll contingencies).

Practical lessons for investors

• Diligence distribution & claims governance in China; review trademark control history and enforcement posture.
• Map each patent to commercialisation; require clinical validation aligned to marketing.
• Assess board operating cadence—are directors prepared to contribute operator‑level effort during crises?
• Test partner resilience: What happens if the counterparty is acquired or pivots strategy?
• Prefer non‑exclusive or performance‑gated exclusives to reduce dependency risk.

Memorable concepts 

• “Three‑legged table → three‑headed monster.” Parallel bets can starve each other.
• “Divest non core assets, including IP” Monetize non‑core/parked IP to recapitalize.
• “The first measure of success is survival.” You must live to fight again.
• “Play hard, but straight.” Values as strategy—trust compounding opens doors.

Get in touch!

We welcome engagement from anyone interested or involved in the early stage investment market – Investors, Angel Members, Strategic or Corporate Partners, Founders, Incubators or Accelerators, Deal Referrers, Acquisition Partners etc.